Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 41 Show results per page	View Search Criteria \| Help With Results


1.		Liver Safety Under Upfront Arimidex vs Tamoxifen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				Not specified				Pharmaceutical / Industry				D5392L00023 NCT00537771


2.		Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				not specified				Other				N07MAN Eudract 2007-007030-20, NCT00684216

Last Modified: 8/9/2007 First Published: 10/1/2002


3.		Phase III Randomized Study of Fluorouracil, Epirubicin, and Cyclophosphamide Versus Docetaxel, Epirubicin, and Cyclophosphamide in Women With Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other				LMU-ADEBAR EU-20221, NCT00047099

Last Modified: 1/14/2009 First Published: 7/26/2003


4.		Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Premenopausal				NCI				IBCSG-2402 BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13

Last Modified: 1/14/2009 First Published: 7/26/2003


5.		Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Premenopausal				NCI				IBCSG-25-02 BIG-3-02, NABCI-IBCSG-25-02, EU-20347, NCT00066703, EUDRACT-2004-000168-28

Last Modified: 4/29/2008 First Published: 10/25/2003


6.		Phase III Randomized Study of Adjuvant Tamoxifen Versus Anastrozole in Postmenopausal Women With Ductal Carcinoma In Situ

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				40 to 70				Other				CRUK-IBIS-II-DCIS EU-20226, BIG-5-02, NCT00072462, IBCSG-31-03-DCIS, ISRCTN31488319


7.		Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				OSU-0476 NCT00293540

Last Modified: 1/14/2009 First Published: 3/24/2006


8.		Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 75				NCI				ECOG-PACCT-1 SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx


9.		Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				D5392NL0003 EUDRAct No: 2005-006167-31, NCT00301457

Last Modified: 6/18/2008 First Published: 2/5/2007


10.		Phase III Randomized Study of 70-Gene Signature Versus Clinical Assessment in Selecting Women With Node-Negative Breast Cancer for Adjuvant Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other, Pharmaceutical / Industry				EORTC-10041 EUDRACT-2005-002625-31, BIG-3-04, NOVARTIS-EORTC-10041, ROCHE-EORTC-10041, SANOFI-AVENTIS-EORTC-10041, NCT00433589

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute